Professor Philip Keith MOORE

B.Sc. Pharm (Hons), University of London, King’s College
Ph.D. (Pharmacology), University of London, King’s College

Department of Pharmacy, National University of Singapore
18 Science Drive 4, Singapore 117543
Tel: +65 6601 1669


Prof Philip Keith Moore has taken on the role of Executive Director of the NUS Graduate School for Integrative Sciences and Engineering (NGS).


Prof Moore first joined NUS in 2003. He was Head of the Department of Pharmacology for almost five years and for the last two years of that period, he was additionally Vice Dean of Research at NUS’ Yong Loo Lin School of Medicine. After spending a few years back in the United Kingdom where he headed the Department of Pharmacology and Therapeutics at King’s College, Prof Moore re-joined NUS in 2010 as a Research Director in the Office of the Deputy President (Research and Technology) with concurrent professorial appointments in the Departments of Pharmacology and Pharmacy.


An internationally- renowned pharmacologist, Prof Moore has published over 150 papers in leading journals and is a highly cited author. He has extensive experience in graduate education in both the UK and Singapore, having guided many students to their PhD degree, which remains one of his fondest achievements.


Prof Moore succeeds Prof Li Baowen, who had led NGS for almost three years and stepped down from the role to dedicate himself fully to his research. Prof Li is a world-leading physicist well-regarded for his pioneering work in phononics and thermoelectrics. NUS is grateful to Prof Li, who has returned to his academic pursuits at the Department of Physics, Faculty of Science, for his significant leadership, contributions and guidance over the years to NGS.

(Information from:


    1. An investigation of the effect of H2S on atherosclerosis
      We have previously reported that H2S exhibits potent vasodilator and anti-inflammatory activity suggesting that this novel gas may play a part in cardiovascular physiology and pathophysiology. This project seeks to determine whether a deficiency of vasculoprotective H2S may precipitate atherosclerotic disease. Experiments will be carried out in ApoE-/- atherosclerotic mice and combined with investigation of blood vessels obtained from human volunteers collected, after informed consent, during coronary artery surgery. The project centres upon an integrative approach involving studies both in animals and in cell culture.
    2. A study of the biological effects of novel H2S donor drugs
      A number of projects are currently under way to determine the biological effects of a range of novel H2S donor agents in inflammation and cardiovascular disease. Possible target for these drugs which are currently being studied include lipopolysaccharide-evoked septic shock and adjuvant-induced knee joint arthritis. A range of techniques including cell culture and associated biochemical and molecular biological characterisation as well as studies in intact animals are ongoing.